How to stop culture killing a deal




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: How to stop culture killing a deal
Released on: June 02, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Steve Twait, Vice President, Alliance and Integration Management at AstraZeneca, discusses the importance of culture in the deal making process, and describes his core personality criteria for all people working in Alliance Management.
  • Summary
  • Transcript
  • Participants
  • Company
Steve Twait, Vice President, Alliance and Integration Management at AstraZeneca, discusses the importance of culture in the deal making process, and describes his core personality criteria for all people working in Alliance Management.
Steve Twait, Vice President, Alliance and Integration Management at AstraZeneca, discusses the importance of culture in the deal making process, and describes his core personality criteria for all people working in Alliance Management.
Steven Twait: Broad pharmaceutical and biotech experience in manufacturing, corporate affairs, procurement, business development, alliance management across entire value chain. Deep experience in managing human risk, business risk and legal uncertainties associated with global strategic partnerships across research, development, and commercialization. Specialties:Alliance Management (contract development, re-negotiations, structuring alliances, governance, dispute resolution), International Alliance Development (significant German and Japanese alliance experience), Relationship Develpment, Merger/Acquisition Integration.
AstraZeneca
AstraZeneca plc is a British-Swedish pharmaceutical company formed on 6 April 1999 by the remerger of Swedish Astra AB and British Zeneca Group plc. Zeneca had been part of Imperial Chemical Industries (ICI), as three divisions that were spun off from ICI on 1 June 1993. It is a public company and is listed on the London Stock Exchange, the New York Stock Exchange and the OMX exchange.